Gxstrands is pleased to announce that our immune-silent single-stranded DNA (ssDNA) platform has been selected as the foundational modality for the QUIET-CAR project, a Eurostars-funded initiative supported by the Eureka Network. This collaborative effort, led by CPTx and Nanocell Therapeutics, aims to develop a pioneering in vivo CAR-T therapy utilizing targeted lipid nanoparticles (LNPs) in combination with immune-silent ssDNA.
The QUIET-CAR project was ranked among the top proposals out of more than 120 applications submitted from 37 countries, underscoring its potential to advance the next generation of gene-modified cell therapies. This recognition highlights both the innovation of the approach and the importance of immune-silent ssDNA as a critical enabling technology.
For more details, please see the official press releases:
To explore how gxstrands’ immune-silent ssDNA can accelerate your therapeutic programs, please contact us at info@gxstrands.com.
